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Trm role ofendogenous nitric oxide (NO) on vascular and
respiratory smooth muscle basal tone was evaluated in
six anaesthetized, paralysed, mechanically ventilated
pigs. The involvement ofendogenous NO in PAF-induced
shock and airway hyperresponsiveness was also studied.
PAF (50 ng/kg, i.v.) was administered before and after
pretreatment with A-nitro-L-arginine methyl ester (L-
NAME, 10 mg/kg, i.v.), anNO synthesis inhibitor. PAFwas
also administered to three of these pigs after
indomethacin infusion (3 mg/kg, i.v.). In normal pigs, L-
NAME increased systemic and pulmonary vascular
resistances, caused pulmonary hypertension and reduced
cardiac output and stroke volume. The pulmonary vascu-
lar responses were correlated with the increase in static
and dynamic lung elastances, without changing lung re-
sistance. Inhibition of NO synthesis enhanced the PAF-
dependent increase in total, intrinsic and viscoelastic
lung resistances, without affecting lung elastances or car-
diac activity. The systemic hypotensive effect ofPAF was
not abolished by pretreatment with L-NAME or
indomethacin. This indicates that systemic hypotension
is not correlated with the release of endogenous NO or
prostacyclines. Indomethacin completely abolished the
PAF-dependent respiratory effects.
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Introduction
It is known that endothelial release of nitric oxide
(NO) acts as a physiological regulator of vascular
tone and blood pressure.1- Because NO is also pro-
duced by several types of pulmonary cells,4,5 it may
be found in respiratory bronchioli and alveoli. The
increased production of NO, found in exhaled air of
asthmatic patients, reflects the role of endogenous
nitric oxide as a modulator of bronchial tone.6,7
Consequently, airway epithelium plays the same role
as endothelium in regulating the tone of underlying
smooth muscle. Recently, a modulatory effect of
epithelium on the contractile responses of airway
smooth muscle to spasmogens has been described.
Airway epithelium plays this critical role in the regu-
lation of airway functions producing not only nitric
oxide, but also a large number of inflammatory
mediators, including prostaglandins, endothelin-1,
and various cytokines. By releasing NO, the
epithelial layer acts as a protective barrier against
spasmogenic agents that are released in inflammatory
disorders.
As suggested by Nijkamp et al., diminished pro-
duction of NO after epithelial damage, typical of
asthma, contributes to airway hyperresponsiveness,
which may be due to a marked release of platelet
activating factor (PAF), a typical inflammatory and
124 Mediators of Inflammation Vol 4 1995
allergic mediator of asthma.1 PAF is a potent
bronchoconstrictor, and also induces strong pul-
monary hypertension and systemic hypotension.
Moritoki et al. 11 have suggested that this systemic
hypotension can be due to production of nitric oxide.
The aim of this present study was to evaluate the
role of endogenous NO on circulatory and respira-
tory systems and its involvement in PAF-induced
shock and bronchoconstriction. To evaluate the role
of endogenous NO in the normal pig or during PAF-
dependent shock, we used N-nitro-t-arginine me-
thyl ester (t-NAME), an arginine analogue, which acts
as an inhibitor of NO synthesis.
Materials and Methods
Six Large White pigs, of either sex, weighing 21.9
+ 1.3 (S.E.M.) kg, were used. The animals, sedated
with 1% propionylpromazine hydrochloride (0.05
ml/kg, i.m.), were anaesthetized with 15 mg/kg
thiopental-sodium injected into the auricular vein.
The depth of anaesthesia was maintained by infu-
sion, drop by drop, of thiopental-sodium (9 mg/kg/
h). The animals, tied in the supine position on a
heated operating table, were tracheostomized, para-
lysed with pancuronium bromide (0.02 mg/kg, i.v.)
and mechanically ventilated (Servoventilator Sie-
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mens 900 C). When necessary, additional paralysing
drug was administered during the experiments.
An endotracheal tube was inserted into the lower
portion of the extrathoracic trachea. A side port of
the tracheal cannula was connected to a pressure
transducer (Statham 15299, Gould, Hatorey, Puerto
Rico) for measurement of tracheal pressure. A heated
pneumotachograph (Fleisch no 2, Fleisch Lausanne,
Switzerland) was connected to the proximal end of
the endotracheal tube and to the ’Y’ piece of the
ventilator to evaluate respiratory flow. Electronic
integration of the flow signal gave the tidal volume.
The pressure drop across the two ports of the
pneumotachograph was measured with a differential
pressure transducer (Statham PM15, 10846). The re-
sponse of the pneumotachograph was linear over the
experimental range of flows. To reduce the effects of
the compliance of the system on the mechanical
measurements, a fixed length standard low-compli-
ance tube was used (2 cm i.d. 60 cm long) to connect
the animals to the ventilator. The equipment’s flow
resistance was 0.5 cmH,.O/1/s and the equipment’s
dead space was 29.5 ml. The intrapleural pressure
was evaluated by an air-filled polyethylene catheter
tied into the lower 7th right intercostal space.
Transpulmonary pressure (P,) was measured as the
difference between tracheal and intrapleural pres-
sure, using a differential pressure transducer
(Validyne MP 45, +__ 100 cmH20; Validyne Inc.,
Northridge, CA, USA). Special care was taken to
avoid air leaks from the tracheal and pleural cannulae
and breathing circuit.
A balloon-tipped catheter (Swan Ganz 5F) was
introduced into the left brachial vein and allowed to
oat through the right heart to the pulmonary artery.
Polyethylene catheters were inserted into the right
femoral artery to record blood pressure and into the
right femoral vein for drug administration. Systemic
and pulmonary arterial pressure were recorded by
connecting the catheters to a fluid-filled capacitance
manometer (Bell & Howell 4-422). Cardiac output
(CO) was evaluated by the thermodilution method
(Cardiac Output Computer 701 IL). All parameters
were calibrated independently and recorded simul-
taneously on a multichannel pen recorder (model
8K40; NEC San-El instruments, Ltd, Tokyo, Japan).
For subsequent analysis of data PL and flow were
also recorded on an FM magnetic tape recorder
(Racal Store 4, Racal Recorders Ltd, Southampton,
UK). The signals were played back to an Olivetti 486
(Ivrea, Italy) personal computer by a 12-bit analogue-
to-digital board at a sample frequency of 2000 Hz.
Heart rate, mean arterial pressure (MAP) and
mean pulmonary arterial pressure (MPAP) were
evaluated from the polygraph tracings. Stroke
volume (SV) and systemic (SVR) and pulmonary
(PVR) vascular resistances were calculated with
standard formulae.
Procedure and data analysis: The baseline ventilator
settings were a fixed inflation volume of 0.2 _+ 0.01
(S.E.M.) and a fixed inspiratory flow of 0.25 + 0.01
(S.E.M.) 1/s. Respiratory frequency was 23 +_ 2
(S.E.M.) breaths/min and the ratio of inspiratory time
to total breathing cycle duration was 0.33 -+ 0.01
(S.E.M.). Respiratory mechanics values were assessed
by the constant flow inspiratory occlusion
method. 12,13 For each breath, airway occlusion was
followed by a rapid initial drop in transpulmonary
pressure (P1) and was maintained until an apparent
plateau (P2), representing the end-inspiratory elastic
recoil pressure, was reached (5-6 s). The difference
between the peak of transpulmonary pressure (Praax)
and plateau pressure, divided by the immediately
preceding steady flow provided the total lung resist-
ance (Rmax.t). The initial pressure drop in PL from Pmax
tO Pl divided by the immediately preceding steady
flow provides the intrinsic resistance of lung (Rint,t).
Dividing Pl-P2 by the pre-occlusion flow we
obtained the additional effective resistance (ARL)
due to the viscoelastic properties of the thoracic
tissues and the time constant inequalities within the
lung. TM The static (Est,) and dynamic (tdyn,t) elastances
of the lung were obtained by dividing P2 or P1 by the
inspiratory volume.
Protocol: After evaluation of control values, PAF
freshly mixed in normal saline solution was admin-
istered i.v. at a dose of 50 ng/kg. 15 When baseline
values had recovered (about 45 min), t-NAME was
administered through the femoral vein at a dose of
10 mg/kg. Preliminary studies showed that this dose
causes vascular effects within 10 min and that these
are stable for at least 120 min. Thirty minutes after t-
NAME pretreatment, PAF was again administered at
the same dose. After recovery from PAF effects,
indomethacin was also administered to three of six
pigs pretreated with t-NAME, through the femoral
vein, at a dose of 3 mg/kg. The pigs were treated
again with PAF 30 min after indomethacin adminis-
tration.
Data analysis and statistics: Results are expressed as
means + S.E.M. The significance of differences be-
tween two sets of data was assessed by the two-tailed
t-test for paired data. A significant difference was
defined as p < 0.05.
Results
The circulatory parameters, evaluated under all
experimental conditions, are given in Table 1. PAF
caused a prompt and short-lasting decrease in mean
arterial pressure and a marked increase in mean
pulmonary arterial pressure. These haemodynamic
changes reached a peak in 10-20 s and were associ-
ated with transient cardiac arrest. While MAP rapidly
returned to control values, pulmonary hypertension
lasted 20 min. The vascular changes were associated
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Table 1. Circulatory parameters in all experimental conditions
MAP MPAP
(mmHg) (mmHg)
SV CO PVR SVR
(ml) (I/min) (mmHg/I/m) (mmHg/I/m)
Control
Mean 6 106.25
S.E.M. 4.54
PAF
Mean 6 58.19
S.E.M. 6.07
p
Control
Mean 6 94.11
S.E.M. 4.27
L-NAME
Mean 6 105.28
S.E.M. 13.64
PAF
Mean 6 44.72
S.E.M. 3.51
p
22.42 28.63 2.59 8.93 42.50
1.68 2.33 0.24 0.79 2.92
56.15 6.16 0.76 81.18 82.34
2.26 1.49 0.10 8.41 9.92
22.82 25.05 2.13 11.11 46.94
2.35 2.81 0.20 1.02 5.30
34.32 15.76 1.34 28.19 79.15
3.49 1.96 0.15 4.84 7.02
47.50 6.15 0.78 84.62 82.29
2.21 2.65 0.20 21.83 22.79
n, number of pigs; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; SV, stroke volume; CO, cardiac output; PVR,
pulmonary vascular resistances; SVR, systemic vascular resistances. *p < 0.05 vs control conditions; Op < 0.05 vs L-NAME administration.
with significant decreases in stroke volume and car-
diac output. PAF administration increased pulmonary
and systemic vascular resistances, but the decrease in
MAP was the cause of the lesser change in SVR.
t-NAME administration did not affect systemic ar-
terial pressure, but significantly increased MPAP. t-
NAME also strongly decreased CO, due to the reduc-
tion in SV, because the heart rate did not change
(data not reported). The changes in cardiac activity
were responsible for the rises in SVR and in PVR.
Pretreatment with t-NAME did not prevent either
systemic hypotension or pulmonary hypertension
caused by PAF administration. In fact, in this case
too, PAF increased MPAP (147.72 _+ 17.55%), even
though this effect was less than that obtained before
t-NAME (263.78 _+ 32.24%, p < 0.05). The t-NAME-
dependent decreases in stroke volume and cardiac
output were strengthened by PAF, which, again,
caused transient cardiac arrest. In pigs pretreated
with t-NAME, the administration of PAF did not
modify the SVR, but caused a further marked increase
in PVR, to values similar to that observed when PAF
was administered before t-NAME. In three of the six
pigs pretreated with t-NAME, indomethacin adminis-
tration did not prevent PAF-dependent systemic
hypotension.
The changes in lung resistances are shown in
Fig. 1. PAF administration caused a marked
bronchoconstriction, all shown by the rise in Rint, and
a large change in the viscoelastic properties of the
lung, reflected by the increase in ARL. Because Rmax,L
is the sum of Rint, and ARL, the increases in intrinsic
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and viscoelastic resistances were the cause of the rise
in the total lung resistance, t-NAME administration
did not affect the resistances of the lung, but did
enhance the effects of PAF on Rint,t, /tg and Rmax,L.
Indomethacin, administered to pigs pretreated with t-
NAME, did not affect pulmonary resistances and
completely abolished the effects of PAF.
Figure 2 shows the changes in static (A) and
dynamic (B) elastances of the lung under all experi-
mental conditions. The results show that PAF admin-
istration significantly increased both static and dy-
namic elastances. Under control conditions t-NAME
significantly increased Est,t and Eyn,t, but did not alter
the effects of PAF on static and dynamic elastances.
In pigs pretreated with t-NAME, the PAF-dependent
rise in Est,t and Edyn, was similar to that observed
without t-NAME. As for lung resistances,
pretreatment with indomethacin associated with t-
NAME prevented PAF-dependent changes in static
and dynamic elastances.
Figure 3 shows the correlation between Est,t and
MPAP. The increases in MPAP and Est,,. caused by t-
NAME or by PAF were similar. When PAF was admin-
istered after pretreatment with t-NAME, the lesser
increase in MPAP was correlated with a greater in-
crease in Est,t.
Discussion
This study shows that endogenous NO acts as a
modulator not only of vascular tone, but also of
bronchial tone. In addition, our data show that thereEndogenous nitric oxide on PAF effects
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FIG. 1. Panel A, total lung resistance (RmaxL); Panel B, intrinsic lung
resistance (Rnt,) and Panel C, viscoelastic lu’g resistance (ARL) under
control conditions (C) and after PAF administered to normal pigs (--),), to
pigs pretreated with L-NAME and to pigs pretreated with L-NAME +
indomethacin (- -). Values are means + S.E.M. *p < 0.05 vs control con-
ditions. Op < 0.05 vs PAF administered under control conditions.
are different NO-mediated regulatory mechanisms in
vascular and respiratory smooth muscle, because
bronchial tone is modulated by NO only when
smooth muscles have been preconstricted by PAF.
The block of NO synthesis by t-NAME increases
pulmonary and systemic vascular resistances, reflect-
ing the modulatory role of NO on vascular smooth
muscle, but did not modify lung resistances. This
lack of change reflects the basal bronchial tone in
pig, which, unlike that in other species, is not af-
fected by inhibition of NO synthesis.
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FIG. 2. Panel A; static lung elastance (Est and Panel B, dynamic lung
elastance (Eun,,) under control conditions () and after PAF administered
to normal pigs (), to pigs pretreated with L-NAME and to pigs
pretreated with L-NAME + indomethacin (- -). Values are means +/- S.E.M.
*p < 0.05 vs control conditions.
Our data also seem to suggest that the sensitivity
to NO differs in the pulmonary and systemic vascular
beds. After t-NAME administration MPAP increased,
while the systemic blood pressure did not. The
increase in MPAP after block of endogenous NO
confirms the data of Persson et al. 16 showing that
pulmonary vascular tone is regulated by nitric oxide.
Even though it is not possible to exclude a difference
in NO sensitivity in the two vascular districts, it seems
probable that the systemic vasoconstrictor effect is
masked by the marked decrease in CO consequent
to an impairment of cardiac activity. The latter effect
may be caused by a sustained coronary vaso-
constriction due to an inhibition of NO synthesis. It
is known that NO is produced continuously by
coronary endothelium17 and, as suggested by Christie
et al., 18a9 the smooth muscle of pig coronary artery is
extremely sensitive to its action. Consequently, a
block of NO, causing coronary ischaemia, may be
responsible for impairment of cardiac activity.
As suggested by Moritoki et al., the release ofNO
may be stimulated by PAF. Consequently, PAF ad-
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FIG. 3. Influence of mean pulmonary arterial pressure (MPAP) on static
lung elastance (Est,L) under all the experimental conditions.
ministration to pigs pretreated with t-NAME would
induce a greater increase in MPAP than that observed
without a block of endogenous NO. It is known that
PAF causes the release ofmany vasoactive mediators,
hence the lesser increase in MPAP we observed in
pigs pretreated with t-NAME may reflect an imbal-
ance between the effects of the vasoconstrictors and
vasodilators. The major vasodilators are NO and
PGI2, which are released in parallel by endothelial
cells. 2,21 The block of NO release alters the coupling
between NO and PGI probably enhancing PGI
activity. An imbalance between vasoconstrictors and
vasodilators may be responsible also of PAF-de-
pendent systemic hypotension. Takekoshi et al. 22
have suggested that the PAF-dependent systemic
hypotension in the dog is due to a release of NO,
while our results, confirming previous data,2 show
the permanence of systemic vasodilatation in pigs
pretreated with t-NAME. This shows that in this
species PAF-dependent systemic hypotension is not
due to release of NO. PGI might also be responsible
for the PAF-dependent systemic hypotension, but
the permanence of this hypotension even after
pretreatment with indomethacin2 shows that the
prostacyclin is not involved in this mechanism.
Hence the prompt and short-lasting PAF-dependent
hypotensive effect associated with a marked de-
crease in CO accounts for the cardiac involvement.
When the effects of t-NAME on the respiratory
system are evaluated, the different regulatory mecha-
nisms of endogenous NO on the basal tones of
pulmonary vascular and bronchial smooth muscle
becomes obvious. Our results show that endogenous
NO block does not affect respiratory resistances, only
vascular resistances. However, Nijkamp et al. who
administered t-NAME by aerosol, suggested that
endogenous NO has a role in the regulation of basal
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bronchial tone. The differences in response might be
due to different methods of administration. Epithelial
cells, as suggested by Nijkamp et al., probably con-
tribute to NO synthesis and, hence, administration of
t-NAME by aerosol may favour the side effects ofNO
inhibition on the epithelial lining of the airway
smooth muscles. The difference between the
intraluminal and extraluminal responses, confirming
the hypothesis of Nijkamp et al., indicates the intrin-
sic role of airway epithelium as a modulator of
bronchial, tone. In pigs, the role of endogenous NO
becomes evident during PAF-dependent
bronchoconstriction. Our results show that the block
of endogenous NO by t-NAME strengthened PAF’s
effects, further increasing the RL. It is known that PAF
is a mediator in many pulmonary inflammatory and
allergic disorders, such as asthma.1 The epithelial
layer in asthmatic patients is often damaged and the
degree of this damage is associated with the degree
of airway hyperresponsiveness. This suggests that
NO produced by airway epithelial cells is involved in
the airway’s defensive mechanisms and in the regu-
lation of bronchial tone. The greater increase in Rmax.L
observed when PAF was administered to pigs
pretreated with t-NAME was due not only to a
bronchoconstrictor effect, as shown by the increase
in Rint,t, but essentially to an increase in ARL. The
latter effect, reflecting the viscoelastic properties of
the lung, is evidence of the parenchymal and vascu-
lar damage caused by PAF. The major effect is pul-
monary hypertension, causing lung oedema. Thus,
the smooth muscle contraction, associated with a
marked pulmonary hypertension and interstitial
oedema, causes the change in ARL and, conse-
quently, in elastance, which seems to be particularly
correlated with the change in MPAP (Fig. 3). The rise
in MPAP due to t-NAME administration is correlated
with a change in elastance even when respiratory
resistance does not change. The greater increase in
Est,t after PAF administration occurs in the presence
of the greater increase in MPAP, and this may induce
more oedema. When PAF was administered after
endogenous NO had been blocked, MPAP increased
less, but the change in Est.L was greater. Combined
administration of t-NAME and PAF, as suggested by
Filep et al.,
24 evokes a significant increase in albumin
extravasation into the pulmonary parenchyma, and
potentiates the vascular permeability effect of PAF.
This may be the reason for the greater change in Est,t
we observed even in the presence of a lower increase
in MPAP, and may reflect the protective role of NO
on the lung.
In conclusion, this study shows that NO is released
by both endothelial and epithelial cells. Inhibition of
NO synthesis by t-NAME administration increases the
inflammatory cell accumulation induced by PAF.25
Thus, nitric oxide may be considered an endogenous
defensive mechanism against inflammatory, obstruc-Endogenous nitric oxide on PAF effects
tive and hypertensive lung diseases, and may be an
important factor in the regulation of airway
hyperresponsiveness and in the maintenance of
bronchial tone. 26,27
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